All In Biotech

Free tool

FAERS Monitor: Cuvrior

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 215760 or its brand name (Cuvrior, Trientine Tetrahydrochloride). Reports on generic versions are filed under their own applications.

Reports

307

Serious

106

35% of reports

Hospitalization

50

Death reported

13

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • off label use79
  • product dose omission issue71
  • nausea22
  • treatment noncompliance21
  • malaise10
  • abdominal pain upper9
  • fatigue9
  • maternal exposure during pregnancy9
  • nasopharyngitis9
  • vomiting9
  • abdominal pain8
  • tremor8
  • abdominal discomfort7
  • asthenia7
  • diarrhoea7

Reports by year received

View as table
YearReports
20171
20222
202321
202486
2025162
202635

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,852 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
treatment noncomplianceSignal2126.317.4487
product dose omission issueSignal7116.513.51,036
maternal exposure during pregnancySignal96.93.640
off label useSignal796.25.1353
nasopharyngitisSignal93.31.813
tremorSignal83.31.711
abdominal pain upperSignal93.01.610
abdominal discomfortSignal72.91.47
abdominal painSignal82.41.25
nausea221.91.39
malaise101.60.82
vomiting91.30.70
asthenia71.30.60
fatigue90.80.40
diarrhoea70.70.40

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.